Gregory R. Friberg, M.D., serves as the Executive Vice President and Chief Research & Development Officer at BioMarin Pharmaceutical Inc., a leading biotechnology company focused on developing and commercializing innovative therapies for serious and life-threatening rare genetic diseases. Dr. Friberg brings a wealth of experience and expertise to his role, having spent over two decades in the biopharmaceutical industry. Prior to joining BioMarin, he held various leadership positions at other prominent companies, including Merck & Co., where he was instrumental in advancing oncology drug development programs. At BioMarin, Dr. Friberg is responsible for overseeing the company's research and development efforts, which include a diverse pipeline of investigational therapies targeting rare diseases. Under his leadership, BioMarin has made significant strides in advancing its clinical programs and bringing new treatments to patients in need. One of Dr. Friberg's notable achievements at the company was the successful development and approval of Voxzogo (vosoritide), a groundbreaking therapy for children with achondroplasia, the most common form of dwarfism. His strategic vision and dedication to scientific excellence have been instrumental in driving BioMarin's growth and success in the rare disease space. In addition to his role at BioMarin, Dr. Friberg is a respected thought leader in the field of rare disease drug development. He has authored numerous scientific publications and frequently speaks at industry conferences, sharing his insights on the latest advancements in the field. Dr. Friberg's passion for improving the lives of patients with rare diseases, combined with his extensive experience and leadership skills, make him an invaluable asset to BioMarin and the broader rare disease community.